Form 8-K Praxis Precision Medicin For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Wall St dips as rising oil prices, hawkish Fed bets pressure stocks
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
August 4, 2025 2:10 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More
Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush
August 4, 2025 1:24 PM EDTWedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.
The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More
Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
August 4, 2025 12:58 PM EDTGuggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $155.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "Key Message: In the open-label RADIANT study (n=37), vormatrigine demonstrated an impressive 56.3% reduction in monthly seizure frequency... More
